Literature DB >> 8277149

Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes.

G D Tollefson1, E Souetre, L Thomander, J H Potvin.   

Abstract

Psychological distress is a driver both of direct and indirect health care costs. Depression compromises functional well-being, such as work productivity. Comorbid anxious features often complicate the recognition of depression and may herald a poor prognosis. We report the results of a cross-sectional naturalistic study to determine the impact of three interventions (no antidepressant, fluoxetine, or tricyclic antidepressant therapy) on relative risk of work days lost in 454 French outpatients with either major or minor depression. Most depressed patients also manifested anxious features (76% with a Hamilton Rating Scale for Anxiety score > or = 12). The presence of anxiety was related to the severity of depression, work absenteeism, and current social instability. Depression severity (Hamilton Rating Scale for Depression score > or = 26, including the contributions of anxious symptoms), psychiatric comorbidity, and psychomotor retardation best predicted continued work absenteeism. Patients with major depression were more likely to receive an antidepressant if they had a past history of depressive episodes and/or previous work disability. Patients with minor depression were less likely to receive drug therapy than patients with major depression, despite their current work disability. Among patients who received fluoxetine or a tricyclic antidepressant for at least 8 weeks, fluoxetine was associated with statistically significantly lower mean anxiety and depression scores and fewer work days missed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8277149     DOI: 10.1097/00004850-199300840-00013

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

1.  The added costs of depression to medical care.

Authors:  K Franco; M Tamburino; N Campbell; J Zrull; C Evans; D Bronson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

2.  Depression and health-related quality of life for low-income African-American women in the U.S.

Authors:  Lori B Frank; Louis S Matza; Dennis A Revicki; Joyce Y Chung
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

Review 3.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

4.  Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.

Authors:  M Nuijten; L Hadjadjeba; C Evans; J van den Berg
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 5.  The economic burden of depression and the cost-effectiveness of treatment.

Authors:  Philip S Wang; Gregory Simon; Ronald C Kessler
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

6.  Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness.

Authors:  Maureen P Boyle; Benedict J Kolber; Sherri K Vogt; David F Wozniak; Louis J Muglia
Journal:  J Neurosci       Date:  2006-02-15       Impact factor: 6.167

7.  Are there meaningful differences between major depressive disorder, dysthymic disorder, and their subthreshold variants?

Authors:  Michael T Moore; Timothy A Brown
Journal:  J Nerv Ment Dis       Date:  2012-09       Impact factor: 2.254

8.  Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.

Authors:  Gavin J Lyndon; Rita Prieto; Dalia B Wajsbrot; Christer Allgulander; Borwin Bandelow
Journal:  Int Clin Psychopharmacol       Date:  2019-05       Impact factor: 1.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.